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iomarkers for
rognostication After
cute Coronary Syndromes
ew Times and Statistics*
hristopher R. deFilippi, MD,†
tephen L. Seliger, MD, MS‡
altimore, Maryland
ix years ago, Morrow and Braunwald (1) recognized the
mportance of a multimarker strategy including assessment
f myocyte necrosis by cardiac troponins, hemodynamic
tress by B-type natriuretic peptide (BNP) or amino termi-
al pro–B-type natriuretic peptide (NT-proBNP), inflam-
ation by high-sensitivity C-reactive protein (hsCRP), and
ascular damage as measured by a measure of renal function
r proteinuria. In the interim, additional studies have
onfirmed the prognostic information and synergism pro-
ided by each arm (2). Furthermore, improvements in the
ensitivity of existing markers and the addition of new
arkers to each arm have added incrementally to risk
tratification models developed on the basis of the proto-
ypical markers (3–6). Early models gave equal weight to
See page 357
ach biomarker (troponin, hsCRP, and BNP) and simply
allied the number of positive markers (7). A more recent
nalysis from the GUSTO (Global Utilization of Strategies
o Open occluded arteries) IV study found that creatinine
learance and troponin elevation provided the greatest
elative contribution to risk (1-year mortality or 30-day
ortality/myocardial infarction) beyond traditional risk fac-
ors and ST-segment depression as compared with NT-
roBNP and hsCRP (8). Recognition of the importance of
roponin levels and renal function for prognostication is
ncorporated into guidelines and widely used in practice to
uide management (9). Does this mean that measurement
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Divisions of †Cardiology and ‡Nephrology, University of Maryland
chool of Medicine, Baltimore, Maryland. Dr. deFilippi reports speaking/consulting
ees ($25,000) each for Roche Diagnostics, Siemens, BG Medicine, and Criticala
iagnostics and research funding ($25,000) each from Roche Diagnostics, Siemens,
G Medicine, and Critical Diagnostics.f hsCRP and natriuretic peptides should be relegated to a
econd tier in the non–ST-segment elevation acute coronary
yndromes (ACS) patients? Timing is perhaps critical.
ypically, biomarker studies of ACS patients have collected
nd reported findings on the basis of a single sample
ollected early in the course of an ACS hospital stay.
lthough some advocate measurement of hsCRP in the first
8 h of ACS, optimal timing for risk stratification with this
arker might be at least 30 days after the event, with the
bility to then interpret levels after the impact of the near
biquitous use of statin therapy (10,11). Interestingly, NT-
roBNP levels also become more predictive of death the
urther out from the index event, indicating that measure-
ent at the time of initial presentation, although predictive,
s less than optimal (12). To put this in perspective, a panel
f similar cardiac and renal risk markers, including a
ensitive troponin I assay, were predictive of cardiovascular
eath with rigorous statistical methodology (as outlined in
ore detail in the following text) in community-dwelling
lderly men with and without known cardiovascular disease,
ndicating that there is substantial prognostic synergistic
nformation that can be derived from all of these biomarkers
hen patients are in a steady state some distance from their
CS event (13). However, not only is the timing of
easurement of a biomarker important, but the change or
bsence of change in level can also carry relevant informa-
ion. Unlike traditional clinical risk factors, which are in
arge part static and often represent decades of prior
xposure, biomarker measurement is dynamic with changes
ver time common, and this change in level (or lack of it)
an be as prognostic as the initial level itself (14,15). For
xample, Eggers et al. (14) have previously shown in the
RISC (FRagmin and fast revascularization during InStability
n Coronary artery disease) II study patients that even a very
inor persistent elevation of cardiac troponin I over 6
onths carries a higher 5-year mortality than those patients
ith only transient elevations.
With emerging data about the importance of temporal
hanges in biomarker levels (which is likely to get even more
omplex with the introduction of increasingly sensitive
roponin assays), clinicians are facing a dilemma as to when
o consider measuring which marker and how often (if at
ll). The present study by Eggers et al. (16) in this issue of
he Journal attempts to rigorously address at least this first
ssue in 2 ways. First, the investigators measure a panel of
iomarkers at randomization, 6 weeks, and 6 months for
-year outcomes of death, myocardial infarction, or both.
ltimately they conclude that only an NT-proBNP level at
he intermediate time point of 6 weeks added significant
rognostic information to statistical models containing con-
entional risk indicators. This conclusion is paradoxical to
arlier publications in the same population and needs to be
nterpreted in light of the application of newer statistical
ests that are being used with increasing frequency in the
ssessment of the incremental value of biomarker testing to
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Biomarkers for ACS July 21, 2009:365–7onventional risk indicators (12,14). The 2 tests included
n this analysis that warrant further discussion are the
-statistic and the net reclassification improvement
NRI) (17).
The c-statistic represents the area under the receiver-
perating curve, a plot of sensitivity versus 1 specificity over
he full range of an individual biomarker or (when applied to
multivariate regression model) the range of predicted
utcome probabilities. The c-statistic is a commonly em-
loyed measure of discrimination (i.e., the capacity of a
iomarker or statistical model to successfully discriminate
hose who experience an outcome from those who do not).
y comparing the c-statistics for 2 prediction models—1
ith the “novel” biomarkers and 1 with standard or tradi-
ional risk factors—one can quantify the incremental gain in
rognostic accuracy.
Although the c-statistic provides a summary of prognos-
ic accuracy that is independent of a specific cut-point of a
iomarker, recently, Cook (18) has questioned its appropri-
teness in identifying biomarkers of potential clinical utility.
irst, it is relatively insensitive for detecting moderately-
ized effects that might still have clinical relevance; for
Figure 1 Proposed Updated Biomarker Prognostic Profile in Ac
Darker shades of colors represent greater prognostic information, and lighter sha
front star represents measurements during the first days of hospital stay. The bac
BNP  B-type natriuretic peptide; eGFR  estimated glomerular filtration rate; HbA
terminal pro–B-type natriuretic peptide. Modified from Morrow and Braunwald (1).xample, Cook demonstrated that widely accepted, estab-
ished cardiovascular risk factors such as systolic blood
ressure and cholesterol are associated with small incremen-
al gains in the c-statistic (0.03 to 0.04) for the prediction of
ardiovascular events. Considered in this context, the 0.03
ain in c-statistic observed after adding NT-proBNP (at 6
eeks or 6 months after ACS) to clinical risk indicators in
RISC II might be considered clinically important. An
dditional limitation of the c-statistic is that it does not take
nto account the magnitude of change in estimated risk
ssociated with adding a biomarker or set of biomarkers to
traditional risk profile, although it is precisely this risk
hange that is of relevance to the clinician. For example, a
linician is more likely to modify his or her clinical manage-
ent if a patient is reclassified to a markedly higher risk
ategory after measurement of a biomarker or set of markers.
The NRI, used by Eggers et al. (16) in this study, is an
stimate of this type of reclassification—the extent to which
biomarker correctly reclassifies individuals to a higher or
ower risk of a specific outcome. The NRI was designed for
tudies in which established clinically relevant risk catego-
ies were considered—for example, the low-, intermediate-,
oronary Syndromes
present less or equivocal prognostic information at the time point tested. The
represents measurements 6 weeks to 6 months after initial presentation.
hemoglobin A1c; hsCRP  high-sensitivity C-reactive protein; NT-proBNP  aminoute C
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July 21, 2009:365–7 Biomarkers for ACSnd high-risk categories defined by the Framingham Risk
core. With these categories, Eggers et al. (16) demonstrate
hat 11% of patients are correctly reclassified into higher or
ower risk categories; interestingly, much of this improve-
ent resulted from patients without an event who were
reviously classified as high risk (with traditional risk
actors) being correctly reclassified as low or intermediate
isk on the basis of their NT-proBNP levels. This 11% net
eclassification compares favorably with the NRI values
eported in other biomarker studies, including hsCRP in the
hysicians Health Study for the prediction of cardiovascular
isease events (5.4%) and troponin-I or NT-proBNP for
rediction of cardiovascular disease mortality in older Swed-
sh men (12% to 15%) (13,19). Whether 11% net reclassi-
cation justifies the routine measurement of NT-proBNP 6
eeks after an ACS event depends in part on cost-
ffectiveness considerations and whether a reclassification to
lower risk category has the same ramifications for clinical
are as reassignment to a higher risk category.
The current study highlights the strengths and limita-
ions of the current statistical methods for quantifying
rognostic accuracy of new biomarkers and risk factors.
etrics such as the c-statistic, the NRI, and related mea-
ures of discrimination, reclassification, and calibration pro-
ide complementary information about prognostic accuracy.
hat is clear is that investigators will need to look beyond
ust biomarkers measured at presentation and statistical tests
f association—relative risks, hazard ratios, and odds ratios—to
ake a compelling argument for the clinical utility of an
lternative marker in cardiovascular risk prediction. There-
ore, we present a modest update to the figure originally
roposed by Morrow and Braunwald (1) to account for the
ndings from Eggers’ work and others cited here, on the
asis of the increasing recognition of the timing of biomar-
er measurement after ACS and new statistical methodol-
gy (Fig. 1).
eprint requests and correspondence: Dr. Christopher R. deFil-
ppi, G3K63, Division of Cardiology, University of Maryland,
2 South Greene Street, Baltimore, Maryland 21201. E-mail:
defilip@medicine.umaryland.edu.
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